# A review of human papillomavirus prevalence and cervical cancer in Myanmar

Source: https://onco.cc/key-papers/paper-win-hpv-cervical-cancer-myanmar-review-2025/  
OnCo record `paper-win-hpv-cervical-cancer-myanmar-review-2025` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A systematic review of cervical cancer and human papillomavirus in Myanmar, drawing on the two regional cancer registries, estimating that 4% of women screened in the community, and 11% of women attending outpatient clinics, carry the virus.

## Summary

Published as "A Review of Human Papillomavirus Prevalence and Cervical Cancer in Myanmar". The authors searched Embase, Global Health, Medline and local databases to 31 May 2024 for observational studies of the virus, precancerous lesions, co-factors and cervical cancer in Myanmar, and pooled prevalence studies by meta-analysis. The full text describes the Yangon population-based cancer registry as covering about 7.3 million people from 2018 to 2020, and the Nay Pyi Taw registry as covering about 1.16 million since 2013, and reports that only 4% of eligible women had ever been screened in 2019 according to WHO.

## Fields

- Kind: Key paper
- Last checked: 2026-11-11
- Journal: Journal of Epidemiology and Global Health
- Year: 2025
- DOI: 10.1007/s44197-025-00436-4
- Authors: Win TZK, Simms K, Thinn MM, et al.
- Findings: The two regional registries reported age-standardised cervical cancer incidence of 14.1 per 100,000 women in Nay Pyi Taw (2013 to 2017) and 19.3 in Yangon (2018), where breast (32.7) and lung cancer (21.7) were more common.; Pooled prevalence of the virus was 4% (95% CI 3 to 5%) in community-based screening of women aged 18 to 65, and 11% (4 to 21%) in outpatient clinic screening; 30.1% among women living with HIV.; Types 16 (60 to 85.7%) and 18 (14.8 to 20%) were the commonest in cervical cancers.; Co-factors included smokeless tobacco use by 24.1% of women and smoking by 8.4%.
- What it means: The review sets out what is known about cervical cancer and human papillomavirus in Myanmar, and how little screening there had been by 2019.
- Caveats: The abstract's sentence on registry rates pairs the Nay Pyi Taw and Yangon figures the other way round from the full text; the figures here follow the full text and the Nay Pyi Taw registry's own paper.; Most included studies predate 2021.

## Sources

- J Epidemiol Glob Health 2025: https://doi.org/10.1007/s44197-025-00436-4
- PubMed: https://pubmed.ncbi.nlm.nih.gov/40560256/
- Europe PMC full text: https://europepmc.org/article/PMC/PMC12198088

## Connected records

- key papers: [Current status of cervical cancer prevention and screening in Myanmar](https://onco.cc/key-papers/paper-thinn-cervical-screening-myanmar-2023/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- institutions: [Nay Pyi Taw Cancer Registry (population-based), Myanmar](https://onco.cc/institutions/nay-pyi-taw-cancer-registry/)

---
JSON: https://onco.cc/api/v1/entities/paper-win-hpv-cervical-cancer-myanmar-review-2025.json